Latest Conference Articles

February 26th 2015, 11:50am

PER® Miami Breast Cancer Conference

The landscape of breast cancer care is shifting rapidly, but that doesn't worry the organizers of the 32nd Annual Miami Breast Cancer Conference.

February 26th 2015, 10:32am

PER® Miami Breast Cancer Conference

With the evolution of treatment under way, OncLive interviewed three world-renowned experts in the field: Joanne L. Blum, MD, PhD, Adam M. Brufsky, MD, PhD, and Harold J. Burstein, MD, PhD.

February 26th 2015, 8:47am

Genitourinary Cancers Symposium (ASCO GU)

Rana R. McKay, MD, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.

February 23rd 2015, 3:29pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses the future of personalized medicine in lymphoma.

February 23rd 2015, 3:10pm

Genitourinary Cancers Symposium (ASCO GU)

The proportion of men diagnosed with intermediate- or high-risk cancer, based on blood PSA level, increased by nearly 6% from 2011 to 2013.

February 23rd 2015, 3:10pm

Genitourinary Cancers Symposium (ASCO GU)

The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients.

February 23rd 2015, 3:10pm

Genitourinary Cancers Symposium (ASCO GU)

Neither sorafenib nor sunitinib improved outcomes when administered after surgery to patients with locally advanced renal cell carcinoma (RCC), according to results from the phase III ASSURE trial, which were presented at a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

February 23rd 2015, 3:10pm

Genitourinary Cancers Symposium (ASCO GU)

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared to those without a history of testicular cancer.

February 23rd 2015, 3:10pm

Genitourinary Cancers Symposium (ASCO GU)

The spliced androgen receptor variant AR-V7 was not shown to be a biomarker for chemotherapy efficacy in advanced prostate cancer, according to a small prospective study presented in a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

February 23rd 2015, 1:56pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Cytogenetic and molecular data are becoming increasingly important in the individualization of treatment for patients of acute myeloid leukemia, according to a presentation by Stefan Faderl, MD, at the 2015 International Congress on Hematologic Malignancies.

February 23rd 2015, 1:29pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center in Houston, discusses the different standard frontline therapies for patients with chronic lymphocytic leukemia.

February 23rd 2015, 9:16am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

The treatment landscape for acute lymphoblastic leukemia (ALL) is changing, pointing to promising new approaches clinicians can use in practice.

February 21st 2015, 2:06pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Jeffrey Jones, MD, presented evidence supporting the integration of obinutuzumab, ibrutinib, ofatumumab, and idelalisib into the frontline setting for patients with chronic lymphocytic leukemia.

February 21st 2015, 1:46pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Although treatments and cure rates have increased significantly over the past 60 years for patients with Hodgkin lymphoma, it is crucial that practitioners stay up-to-date on research that can affect outcomes for their patients with this uncommon form of cancer.

February 21st 2015, 11:14am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Standard chemotherapy remains part of the treatment paradigm for patients with chronic lymphocytic leukemia but its role is undergoing a major shift as significant advances are being made in novel therapies.

February 20th 2015, 4:02pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.

February 20th 2015, 2:56pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

The treatment options for patients with relapsed/refractory multiple myeloma are expanding rapidly, notably through clinical trial evidence supporting a number of three-drug combination regimens, according to Sundar Jagannath, MD.

February 20th 2015, 1:46pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

The indolent nature of follicular lymphoma and the range of treatment options currently available or in development may create complicated questions regarding how to best use and sequence these therapies.

February 20th 2015, 12:03pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Steven Treon, MD, PhD, from the Dana-Farber Cancer Institute, discusses the game-changing discoveries in Waldenstrom's Macroglobulinemia that led to the approval of ibrutinib for treatment of the disease.

February 20th 2015, 10:05am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses the recent approval of lenalidomide as a therapy for patients with multiple myeloma.